Literature DB >> 26873085

Non-HFE iron overload as a surrogate marker of disease severity in patients of liver cirrhosis.

Mohd Talha Noor1, Manish Tiwari2, Ravindra Kumar3.   

Abstract

BACKGROUND: Decompensated liver cirrhosis is an important cause of mortality worldwide. Various modifiable and non-modifiable factors are involved in the pathogenesis of cirrhosis and its complications. This study was aimed to evaluate the association of iron overload and disease severity in patients of liver cirrhosis and its association with HFE gene mutation.
METHODS: Forty-nine patients with decompensated liver cirrhosis were recruited. Clinical and laboratory parameters were compared in patients with and without iron overload. C282Y and H63D gene mutation analysis was performed in all patients with iron overload.
RESULTS: Iron overload was found in 20 (40.82%) patients. A significant positive correlation of transferrin saturation with Child-Turcotte-Pugh (CTP) score (r = 0.705, p < 0.001) and model for end-stage liver disease (MELD) score (r = 0.668, p < 0.001) was found. Transferrin saturation was also independently associated with high CTP and MELD score on multivariate analysis. Mortality over 3 months was significantly more common in iron-overloaded patients (p = 0.028). C282Y homozygosity or C282Y/H63D compound heterozygosity was not found in any of the patients with iron overload.
CONCLUSION: Iron overload was significantly associated with disease severity and reduced survival in patients of decompensated liver cirrhosis.

Entities:  

Keywords:  CTP score; HFE gene mutation; Iron overload; Liver cirrhosis; MELD score

Mesh:

Substances:

Year:  2016        PMID: 26873085     DOI: 10.1007/s12664-016-0623-6

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  27 in total

Review 1.  Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases.

Authors:  Silvia Fargion; Luca Valenti; Anna Ludovica Fracanzani
Journal:  Dig Liver Dis       Date:  2010-08-24       Impact factor: 4.088

2.  A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.

Authors:  J N Feder; A Gnirke; W Thomas; Z Tsuchihashi; D A Ruddy; A Basava; F Dormishian; R Domingo; M C Ellis; A Fullan; L M Hinton; N L Jones; B E Kimmel; G S Kronmal; P Lauer; V K Lee; D B Loeb; F A Mapa; E McClelland; N C Meyer; G A Mintier; N Moeller; T Moore; E Morikang; C E Prass; L Quintana; S M Starnes; R C Schatzman; K J Brunke; D T Drayna; N J Risch; B R Bacon; R K Wolff
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

3.  Serum ferritin predicts early mortality in patients with decompensated cirrhosis.

Authors:  Rakhi Maiwall; Suman Kumar; A K Chaudhary; Jaswinder Maras; Zeeshan Wani; Chandan Kumar; A Rastogi; C Bihari; Chitranshu Vashisht; S K Sarin
Journal:  J Hepatol       Date:  2014-03-26       Impact factor: 25.083

4.  Does this patient with liver disease have cirrhosis?

Authors:  Jacob A Udell; Charlie S Wang; Jill Tinmouth; J Mark FitzGerald; Najib T Ayas; David L Simel; Michael Schulzer; Edwin Mak; Eric M Yoshida
Journal:  JAMA       Date:  2012-02-22       Impact factor: 56.272

Review 5.  The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club.

Authors:  Kevin P Moore; Florence Wong; Pere Gines; Mauro Bernardi; Andreas Ochs; Francesco Salerno; Paolo Angeli; Michael Porayko; Richard Moreau; Guadelupe Garcia-Tsao; Wladimiro Jimenez; Ramon Planas; Vicente Arroyo
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

Review 6.  Hepatic iron overload and hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

7.  Hepatitis C, iron status, and disease severity: relationship with HFE mutations.

Authors:  Bruce Y Tung; Mary J Emond; Mary P Bronner; Stuart D Raaka; Scott J Cotler; Kris V Kowdley
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

8.  Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver.

Authors:  Elisabetta Bugianesi; Paola Manzini; Sergio D'Antico; Ester Vanni; Filomena Longo; Nicola Leone; Paola Massarenti; Antonio Piga; Giulio Marchesini; Mario Rizzetto
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

Review 9.  Hemochromatosis and alcoholic liver disease.

Authors:  Linda M Fletcher; Lawrie W Powell
Journal:  Alcohol       Date:  2003-06       Impact factor: 2.405

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  2 in total

Review 1.  Immune Dysfunction in Cirrhosis.

Authors:  Mohd Talha Noor; Piyush Manoria
Journal:  J Clin Transl Hepatol       Date:  2017-03-10

2.  Hemochromatosis in India: First Report of Whole Exome Sequencing With Review of the Literature.

Authors:  Abraham Koshy; Roy J Mukkada; Antony P Chettupuzha; Jose V Francis; Julio C Kandathil; Pushpa Mahadevan
Journal:  J Clin Exp Hepatol       Date:  2019-04-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.